May 22, 2009
Gilead Sciences Announces Changes to Cardiovascular R&D Organization Leadership
FOSTER CITY, Calif.--(BUSINESS WIRE)--May. 22, 2009--
Gilead Sciences, Inc. (Nasdaq:GILD) today announced, as part of the
ongoing integration of CV Therapeutics, changes to the company’s
cardiovascular research and development organization leadership. Louis
G. Lange, MD, PhD has decided to assume a part-time position at Gilead
and will therefore be transitioning from his role as Executive Vice
President, Cardiovascular Therapeutics.
With this transition, Gilead’s cardiovascular research and development
organization will report to Norbert Bischofberger, PhD, Gilead’s
Executive Vice President, Research and Development and Chief Scientific
Officer. Luiz Belardinelli, MD, Senior Vice President, Cardiovascular
Therapeutics, will serve as therapeutic area head for cardiovascular
therapeutics, based in Palo Alto and reporting to Dr. Bischofberger.
“Lou has played an integral role in the newly combined Gilead
organization, helping us achieve significant progress with integration
of our cardiovascular R&D operations. In his new role, Lou will continue
to provide valuable insight and input into our research and development
programs in cardiovascular disease,” said John C. Martin, PhD, Chairman
and Chief Executive Officer. “Under Norbert’s leadership, I am confident
that we will be able to advance clinical and research programs as
efficiently as possible, and ultimately bring forward new therapies that
represent significant advancements for patients.”
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops
and commercializes innovative therapeutics in areas of unmet medical
need. The company’s mission is to advance the care of patients suffering
from life-threatening diseases worldwide. Headquartered in Foster City,
California, Gilead has operations in North America, Europe and Australia.
This press release includes forward-looking statements, within the
meaning of the Private Securities Litigation Reform Act of 1995, that
are subject to risks, uncertainties and other factors, including the
risks related to our ability to advance product candidates in our
pipeline. These risks, uncertainties and other factors could cause
actual results to differ materially from those referred to in the
forward-looking statements. The reader is cautioned not to rely on these
forward-looking statements. These and other risks are described in
detail in Gilead’s Annual Report on Form 10-K for the year ended
December 31, 2008 and its Quarterly Report on Form 10-Q for the first
quarter of 2009, as filed with the U.S. Securities and Exchange
Commission. All forward-looking statements are based on information
currently available to Gilead, and Gilead assumes no obligation to
update any such forward-looking statements.
For more information on Gilead, please call the Gilead Public Affairs
Department at 1-800-GILEAD-5 (1-800-445-3235) or visit www.gilead.com.
Source: Gilead Sciences, Inc.
Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715 (Investors)
Amy
Flood, 650-522-5643 (Media)
